
New Orleans — Results of a multicenter phase 3, randomized, double-blind, placebo-controlled trial demonstrate the safety and efficacy of a subantimicrobial-dose (SD) of doxycycline for the treatment of rosacea, said Diane M. Thiboutot, M.D., at the 63rd Annual Meeting of the American Academy of Dermatology here.